complete Privacy Act Statement in the **Federal Register** (65 FR 19477, Apr. 11, 2000). This statement is also available at *http://DocketInfo.dot.gov*.

Background

On August 31, 2007, FMCSA published a notice of receipt of Federal diabetes exemption applications from eighteen individuals, and requested comments from the public (72 FR 50443). The public comment period closed on October 1, 2007, and no comments were received.

FMCSA has evaluated the eligibility of the eighteen applicants and determined that granting the exemptions to seventeen of these individuals would achieve a level of safety equivalent to, or greater than, the level that would be achieved by complying with the current regulation, 49 CFR 391.41(b)(3).

FMCSA is awaiting additional medical information regarding Mr. Ronald C. Vertucci, Jr. from his physician prior to issuing a final decision on his exemption application.

Diabetes Mellitus and Driving Experience of the Applicants

The Agency established the current standard for diabetes in 1970 because several risk studies indicated that diabetic drivers had a higher rate of crash involvement than the general population. The diabetes rule provides that "A person is physically qualified to drive a commercial motor vehicle if that person has no established medical history or clinical diagnosis of diabetes mellitus currently requiring insulin for control" (49 CFR 391.41(b)(3)).

FMCSA established its diabetes exemption program, based on the Agency's July 2000 study entitled "A Report to Congress on the Feasibility of a Program to Qualify Individuals with Insulin-Treated Diabetes Mellitus to Operate in Interstate Commerce as Directed by the Transportation Act for the 21st Century." The report concluded that a safe and practicable protocol to allow some drivers with ITDM to operate CMVs is feasible.

¹The 2003 notice in conjunction with the November 8, 2005 (70 FR 67777) **Federal Register** Notice provides the current protocol for allowing such drivers to operate CMVs in interstate commerce.

These eighteen applicants have had ITDM over a range of 1 to 37 years. These applicants report no hypoglycemic reaction that resulted in loss of consciousness or seizure, that required the assistance of another person, or resulted in impaired cognitive function without warning symptoms in the past 5 years (with one year of stability following any such episode). In each case, an endocrinologist has verified that the driver has demonstrated willingness to properly monitor and manage their diabetes, received education related to diabetes management, and is on a stable insulin regimen. These drivers report no other disqualifying conditions, including diabetes-related complications.

The qualifications and medical condition of each applicant were stated and discussed in detail in the August 31, 2007, **Federal Register** Notice (72 FR 50443). Therefore, they will not be repeated in this notice.

Basis for Exemption Determination

Under 49 U.S.C. 31136(e) and 31315, FMCSA may grant an exemption from the diabetes standard in 49 CFR 391.41(b)(3) if the exemption is likely to achieve an equivalent or greater level of safety than would be achieved without the exemption. The exemption allows the applicants to operate CMVs in interstate commerce.

To evaluate the effect of these exemptions on safety, FMCSA considered medical reports about the applicants' ITDM and vision, and reviewed the treating endocrinologist's medical opinion related to the ability of the driver to safely operate a CMV while using insulin.

Consequently, FMCSA finds that exempting these applicants from the diabetes standard in 49 CFR 391.41(b)(3) is likely to achieve a level of safety equal to that existing without the exemption.

Conditions and Requirements

The terms and conditions of the exemption will be provided to the applicants in the exemption document and they include the following: (1) That each individual submit a quarterly monitoring checklist completed by the treating endocrinologist as well as an annual checklist with a comprehensive medical evaluation; (2) that each individual reports within 2 business days of occurrence, all episodes of severe hypoglycemia, significant complications, or inability to manage diabetes; also, any involvement in an accident or any other adverse event in a CMV or personal vehicle, whether or not they are related to an episode of hypoglycemia; (3) that each individual provide a copy of the ophthalmologist's or optometrist's report to the medical examiner at the time of the annual medical examination; and (4) that each individual provide a copy of the annual medical certification to the employer for retention in the driver's qualification file, or keep a copy in his/her driver's qualification file if he/she is selfemployed. The driver must also have a copy of the certification when driving, for presentation to a duly authorized Federal, State, or local enforcement official.

Discussion of Comments

FMCSA received no comments in this proceeding.

Conclusion

There were no comments to the docket, therefore, based upon its evaluation of the eighteen exemption applications, FMCSA exempts, Stephen B. Atkinson, Thomas G. Blatchley, Jr., George T. Brawner, Anthony J. Clark, Jim E. Chester, Brian S. Fenley, Carroll D. Fetcher, James R. Hudson, Gaines E. Mathis, Thomas F. Meade, Jerry D. Schoolman, Michael Shuler, Kenneth G. Steinkamp, Mark T. Swanberg, Chad L. Udy, Jeffrey S. Volkman, and Kendall H. Wilson from the ITDM standard in 49 CFR 391.41(b)(3), subject to the conditions listed under "Conditions and Requirements" above.

In accordance with 49 U.S.C. 31136(e) and 31315 each exemption will be valid for two years unless revoked earlier by FMCSA. The exemption will be revoked if: (1) The person fails to comply with the terms and conditions of the exemption; (2) the exemption has resulted in a lower level of safety than was maintained before it was granted; or (3) continuation of the exemption would not be consistent with the goals and objectives of 49 U.S.C. 31136(e) and 31315. If the exemption is still effective at the end of the 2-year period, the person may apply to FMCSA for a renewal under procedures in effect at that time.

Issued on: October 15, 2007.

Larry W. Minor,

Associate Administrator for Policy and Program Development.

[FR Doc. E7–20651 Filed 10–18–07; 8:45 am] BILLING CODE 4910–EX–P

DEPARTMENT OF TRANSPORTATION

Saint Lawrence Seaway Development Corporation

Advisory Board; Notice of Meeting

Pursuant to Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463; 5 U.S.C. App. I), notice is hereby given of a meeting of the Advisory Board of the Saint Lawrence Seaway Development Corporation (SLSDC), to be held from 10 a.m. to 11:30 a.m. (EST) on Thursday, November 15, 2007, at the Corporation's Administration Headquarters, Suite W32–300, 1200 New Jersey Avenue, SE., Washington, DC, via conference call. The agenda for this meeting will be as follows: Opening Remarks; Consideration of Minutes of Past Meeting; Quarterly Report; Old and New Business; Closing Discussion; Adjournment.

Attendance at the meeting is open to the interested public but limited to the space available. With the approval of the Administrator, members of the public may present oral statements at the meeting. Persons wishing further information should contact, not later than November 9, 2007, Anita K. Blackman, Chief of Staff, Saint Lawrence Seaway Development Corporation, Suite W32–300, 1200 New Jersey Avenue, SE., Washington, DC 20590; 202–366–0091.

Any member of the public may present a written statement to the Advisory Board at any time.

Issued at Washington, DC, on October 15, 2007.

Collister Johnson, Jr.,

Administrator.

[FR Doc. E7–20645 Filed 10–18–07; 8:45 am] BILLING CODE 4910–61–P

DEPARTMENT OF THE TREASURY

United States Mint

Notification of American Buffalo Gold Proof Coin and American Eagle Gold Proof and Uncirculated Coin Price Increases

Summary: The United States Mint is adjusting prices for its American Buffalo Gold Proof Coin and American Eagle Gold Proof and Uncirculated Coins.

Pursuant to the authority that 31 U.S.C. 5111(a) and 5112(A)(7-11), & (q) grant the Secretary of the Treasury to mint and issue gold coins, and to prepare and distribute numismatic items, the United States Mint produces and issues 2007 American Buffalo Gold Proof Coins in a one-ounce version and American Eagle Gold Proof and Uncirculated Coins in four denominations with the following weights: One-ounce, one-half ounce, one-quarter ounce, and one-tenth ounce. The United States Mint also produces American Eagle Proof and Uncirculated four-coin sets that contain one coin of each denomination. In accordance with 31 U.S.C. 9701(b)(2)(B), the United States Mint is changing the price of these coins to reflect the increase in

value of the underlying precious metal content of the coins—the result of increases in the market price of gold.

Accordingly, effective October 12, 2007, the United States Mint will commence selling the following 2007 American Eagle Proof and Uncirculated Gold Coins and the 2007 American Buffalo Gold Proof Coin according to the following price schedule:

Description	Price
American Buffalo Gold Proof Coins: One-ounce proof buffalo coin American Eagle Gold Proof	\$899.95
Coins: One-ounce gold coin One-half ounce gold coin One-quarter ounce gold coin One-tenth ounce gold coin Four-coin gold set American Eagle Gold Uncir-	Sold Out 459.95 239.95 116.95 1,695.95
culated Coins: One-ounce gold coin One-half ounce gold coin One-quarter ounce gold coin One-tenth ounce gold coin Four-coin gold set	831.95 424.95 219.95 99.95 1,559.95

For Further Information Contact: Gloria C. Eskridge, Associate Director for Sales and Marketing; United States Mint; 801 Ninth Street, NW.; Washington , DC 20220; or call 202– 354–7500.

Authority: 31 U.S.C. 5111, 5112 & 9701

Dated: October 15, 2007.

Edmund C. Moy,

Director, United States Mint. [FR Doc. E7–20616 Filed 10–18–07; 8:45 am] BILLING CODE 4910-02–P

DEPARTMENT OF THE TREASURY

United States Mint

Notification of Citizens Coinage Advisory Committee November 2007 Public Meeting

Summary: Pursuant to United States Code, Title 31, section 5135(b)(8)(C), the United States Mint announces the Citizens Coinage Advisory Committee (CCAC) public meeting scheduled for November 13, 2007.

Date: November 13, 2007.

Time: Public meeting time: 9 a.m. to 11 a.m.

Location: United States Mint, 801 9th Street NW., Washington, DC 20220.

Subject: Review candidate designs for the Abraham Lincoln Commemorative Coin, and other general business.

Interested persons should call 202–354– 7502 for the latest update on meeting time and room location.

In accordance with 31 U.S.C. 5135, the CCAC:

• Advises the Secretary of the Treasury on any theme or design proposals relating to circulating coinage, bullion coinage, Congressional Gold Medals, and national and other medals.

• Advises the Secretary of the Treasury with regard to the events, persons, or places to be commemorated by the issuance of commemorative coins in each of the five calendar years succeeding the year in which a commemorative coin designation is made.

• Makes recommendations with respect to the mintage level for any commemorative coin recommended.

For Further Information Contact: Cliff Northup, United States Mint Liaison to the CCAC; 801 9th Street, NW.; Washington, DC 20220; or call 202–354–7200.

Any member of the public interested in submitting matters for the CCAC's consideration is invited to submit them by fax to the following number: 202–756–6830.

Authority: 31 U.S.C. 5135(b)(8)(C).

Dated: October 12, 2007.

Edmund C. Moy,

Director, United States Mint.

[FR Doc. E7–20615 Filed 10–18–07; 8:45 am] BILLING CODE 4810–02–P

DEPARTMENT OF VETERANS AFFAIRS

Clinical Science Research and Development Service Cooperative Studies Scientific Merit Review Board; Notice of Meeting

The Department of Veterans Affairs (VA) gives notice under Public Law 92– 463 (Federal Advisory Committee Act) that a meeting of the Clinical Science Research and Development Service Cooperative Studies Scientific Merit Review Board will be held on December 12, 2007, at the Saint Gregory Hotel, 2033 M Street, NW., Washington, DC. The meeting is scheduled to begin at 8 a.m. and end at 5 p.m.

The Board advises the Chief Research and Development Officer through the Director of the Clinical Science Research and Development Service on the relevance and feasibility of proposed projects and the scientific validity and propriety of technical details, including protection of human subjects.

The session will be open to the public from 8 a.m. to 8:30 a.m. for the discussion of administrative matters and the general status of the program. The session will be closed from 8:30 a.m. to 5 p.m. for the Board's review of research and development applications.

During the closed portion of the meeting, discussions and recommendations will deal with qualifications of personnel conducting the studies, staff and consultant critiques of research proposals and